American Diabetes Association (ADA) Preview: key themes
SUMMARY At this year's American Diabetes Association (ADA) conference we will be paying particularly close attention to Roche's once-weekly... In Drug Watch/ June, 2010 ASCO 2010: Emerging agents to change the landscape of ovarian cancer treatment
SUMMARY With few treatment options and a poor prognosis, ovarian cancer represents a considerable opportunity for drug developers. Currently... In Drug Watch/ June, 2010 ASCO 2010: Positive data positions Amgen's Prolia as a superior treatment option to Novartis Zometa across a variety of indications
SUMMARY A wealth of data presented at ASCO is adding credibility to the idea of using Prolia as a superior treatment option to Zometa in the... In Drug Watch/ June, 2010 ASCO 2010: Sales upside expected for Celgene's Revlimid and Roche / Biogen Idec's Rituxan following positive data in maintenance settings
SUMMARY Positive data reported today and yesterday at ASCO have expanded the market potential of Revlimid and Rituxan to include first-line... In Drug Watch/ June, 2010 ASCO 2010: Molecularly targeted trials in lung cancer. Does c-Met, not IGF-R or TRAIL, therapy hold blockbuster potential?
SUMMARY Data presented ASCO has cast doubt on the use of IGF-R and TRAIL pathway nteractors for the treatment of NSCLC. However, new data... In Drug Watch/ June, 2010 A pre-view of ASCO: Top themes and hot topics
SUMMARY At this year's American Society of Clinical Oncology Conference (ASCO), we will primarily be keeping an eye on Pfizer's PF-2341066, a first-... In Drug Watch/ May, 2010 FDA approves Dendreon's Provenge (sipuleucel-T)
Analysis of: FDA approves Dendreon's Provenge (sipuleucel-T)SUMMARY Yesterday (29th April 2010), the FDA approved Dendreon's Provenge (sipuleucel-T)... In Drug Watch/ April, 2010